CL2025000320A1 - Proteínas y conjugados de unión al receptor de transferrina - Google Patents

Proteínas y conjugados de unión al receptor de transferrina

Info

Publication number
CL2025000320A1
CL2025000320A1 CL2025000320A CL2025000320A CL2025000320A1 CL 2025000320 A1 CL2025000320 A1 CL 2025000320A1 CL 2025000320 A CL2025000320 A CL 2025000320A CL 2025000320 A CL2025000320 A CL 2025000320A CL 2025000320 A1 CL2025000320 A1 CL 2025000320A1
Authority
CL
Chile
Prior art keywords
conjugates
binding proteins
tfr binding
human
proteins
Prior art date
Application number
CL2025000320A
Other languages
English (en)
Inventor
Alam Riazul
Alvarado Alberto
Hoyt Andrews Forest
Alan Babb Nicholas
Balasubramaniam Deepa
Chauvigne-Hines Lacie
S Cortez Guillermo
Eugene Croy Johnny
Albert Driver David
Edward Fellows Ross
Girard Daniel
C Gonzalez Valcarcel Isabel
Hosahalli Kulkarni Nalini
Alan Lawrence Scott
Liu Feng
Tani Hiroaki
S York Jeremy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2025000320A1 publication Critical patent/CL2025000320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción se proporcionan proteínas que comprenden un dominio de unión a TfR monovalente humano (“proteínas de unión a TfR humanos”), proteínas que comprenden un dominio de unión a TfR monovalente de ratón (“proteínas de unión a TfR de ratón”), conjugados que comprenden tales proteínas de unión a TfR humanos o de ratón, p. ej., conjugados de proteínas de unión a TfR humano-ARNbc, composiciones farmacéuticas que comprenden proteínas o conjugados de unión a TfR humanos, y métodos para tratar enfermedades del SNC (p. ej., enfermedad neurodegenerativa, tal como sinucleinopatía o tauopatía neurodegenerativa) usando proteínas o conjugados de unión a TfR humano.
CL2025000320A 2022-08-08 2025-01-31 Proteínas y conjugados de unión al receptor de transferrina CL2025000320A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263396065P 2022-08-08 2022-08-08
US202363496465P 2023-04-17 2023-04-17

Publications (1)

Publication Number Publication Date
CL2025000320A1 true CL2025000320A1 (es) 2025-05-23

Family

ID=89852508

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025000320A CL2025000320A1 (es) 2022-08-08 2025-01-31 Proteínas y conjugados de unión al receptor de transferrina

Country Status (18)

Country Link
US (1) US20240059784A1 (es)
EP (1) EP4568701A2 (es)
JP (1) JP2025528797A (es)
KR (1) KR20250048566A (es)
CN (1) CN120018860A (es)
AU (1) AU2023323908A1 (es)
CA (1) CA3263853A1 (es)
CL (1) CL2025000320A1 (es)
CO (1) CO2025001246A2 (es)
CR (1) CR20250044A (es)
DO (1) DOP2025000021A (es)
IL (1) IL318768A (es)
JO (1) JOP20250030A1 (es)
MA (1) MA71741A (es)
MX (1) MX2025001590A (es)
PE (1) PE20250839A1 (es)
TW (2) TW202540194A (es)
WO (1) WO2024036096A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026504639A (ja) * 2022-12-05 2026-02-06 イーライ リリー アンド カンパニー 修飾オリゴヌクレオチド
WO2024263567A2 (en) * 2023-06-21 2024-12-26 Eli Lilly And Company Compounds for the delivery of granulin across the blood brain barrier
AU2024326438A1 (en) 2023-08-22 2026-04-02 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025085352A1 (en) * 2023-10-18 2025-04-24 Eli Lilly And Company Transferrin receptor binding proteins and uses thereof
WO2025166119A1 (en) * 2024-02-02 2025-08-07 Eli Lilly And Company Transferrin receptor binding proteins and conjugates
WO2025250605A1 (en) * 2024-05-31 2025-12-04 Eli Lilly And Company Acvr2a and acvr2b rna interference agents
WO2025250642A2 (en) 2024-05-31 2025-12-04 Eli Lilly And Company Transferrin receptor (tfr)-binding variable domains of a heavy chain only antibody (vhh), conjugates and uses thereof
WO2025264602A1 (en) 2024-06-18 2025-12-26 Eli Lilly And Company PRNP RNAi AGENTS
WO2026072446A1 (en) 2024-09-25 2026-04-02 Eli Lilly And Company Conjugates comprising bis-mspt linker
WO2026075889A1 (en) * 2024-10-04 2026-04-09 Eli Lilly And Company Compositions comprising a progranulin domain for the prevention and treatment of neurodegenerative diseases
WO2026080661A1 (en) * 2024-10-10 2026-04-16 Eli Lilly And Company Sod1 rna interference agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
RU2711552C2 (ru) * 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
WO2014189973A2 (en) * 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
US9994641B2 (en) * 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
GB201418713D0 (en) * 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
WO2016090337A1 (en) * 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
JP2019513371A (ja) * 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof

Also Published As

Publication number Publication date
TW202423977A (zh) 2024-06-16
EP4568701A2 (en) 2025-06-18
AU2023323908A1 (en) 2025-02-27
US20240059784A1 (en) 2024-02-22
IL318768A (en) 2025-04-01
CO2025001246A2 (es) 2025-02-13
MA71741A (fr) 2025-05-30
CN120018860A (zh) 2025-05-16
CR20250044A (es) 2025-03-05
WO2024036096A2 (en) 2024-02-15
JP2025528797A (ja) 2025-09-02
KR20250048566A (ko) 2025-04-09
PE20250839A1 (es) 2025-03-21
DOP2025000021A (es) 2025-03-31
WO2024036096A3 (en) 2024-04-25
TW202540194A (zh) 2025-10-16
MX2025001590A (es) 2025-03-07
TWI882406B (zh) 2025-05-01
CA3263853A1 (en) 2024-02-15
JOP20250030A1 (ar) 2025-02-06

Similar Documents

Publication Publication Date Title
CL2025000320A1 (es) Proteínas y conjugados de unión al receptor de transferrina
CO2019004203A2 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
CO2021016552A2 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
MX2021005822A (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr.
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
CL2023000683A1 (es) Moléculas de unión a b7-h4 terapéuticas
MX2020007077A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
NI202000071A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
UA122331C2 (uk) Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
CL2025002824A1 (es) Nueva molécula de unión
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
CL2025002297A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa.
CO2022011183A2 (es) Conjugados de proteínas-compuestos antivirales
CL2024001486A1 (es) Conjugados peptidicos de inhibidores peptidicos de tubulina como terapeuticos.
AR130145A1 (es) Proteínas y conjugados de unión al receptor de transferrina
AR134149A1 (es) Proteínas de unión al receptor de transferrina y usos de estas
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas